

## 1.16 Release Notes

### Changes

---

#### Warning Messages

---

##### Addition of Omicron Variant booster warning messages.

We have received an addendum to the Point of Care System Specification that details 4 changes.

- Provision of a new warning message when a booster dose is selected for an individual for whom a booster dose has already been administered
- Warning messages for scenarios where minimum intervals (based on age and clinical circumstances) between vaccine doses are not met for individuals
- Vaccinations administered to a Severely Immunosuppressed individual to be captured so to trigger supplementary payment
- Updated information on the minimum interval between all COVID-19 doses for:
  - Adults (18+)
  - Children (16-17)
  - Children (12-15)

To help explain the new dosing and scheduling interval changes for the different age groups please see the charts below.

Changes from previous dose and scheduling intervals are highlighted in **green**.

Adults 18 years of age and over:

Vaccine Name	Scheduling				Dose Amounts	
	Minimum interval between 1 <sup>st</sup> and 2 <sup>nd</sup> dose	Minimum interval between 2 <sup>nd</sup> and subsequent primary course doses where required	Minimum interval between primary course and booster doses	Minimum interval between booster doses [2]	Primary course	Booster dose
<b>Comirnaty®</b> (PfizerBioNtech)	56 days	56 days	91 days	91 days	0.3ml	0.3ml
<b>AstraZeneca [3]</b>	56 days	56 days	91 days	91 days	0.5ml	0.5ml
<b>Spikevax®</b> (Moderna)	56 days	56 days	91 days	91 days	0.5ml	0.25ml

**Note:**

[1] Maximum interval between doses has been removed

[2] Only adults within the severely immunosuppressed cohort should be able to have a second booster dose recorded. In normal circumstances, this will be a true booster dose for this cohort, as their first booster is likely to have been their 3<sup>rd</sup> dose (primary course)

[3] AstraZeneca is not currently authorised for under 40s, however, in exceptional circumstances, where Comirnaty® (PfizerBioNtech) or Spikevax® (Moderna) are unavailable or not appropriate for individuals, AstraZeneca may be considered if approved by a lead clinician

16 to 17 years of age inclusive

Vaccine Name	Scheduling				Dose Amounts	
	Minimum interval between 1 <sup>st</sup> and 2 <sup>nd</sup> dose [1]	Minimum interval between 2 <sup>nd</sup> and subsequent primary course doses where required [2]	Minimum interval between primary course and booster doses [2]	Minimum interval between booster doses [2]	Primary course	Booster dose
<b>Comirnaty®</b> (PfizerBioNtech)	84 days	56 days	91 days	91 days	0.3ml	0.3ml
<b>AstraZeneca [3]</b>	84 days	56 days	91 days	91 days	0.5ml	0.5ml
<b>Spikevax® [3]</b> (Moderna)	84 days	56 days	91 days	91 days	0.5ml	0.25ml

**Note:**

[1] For individuals in this cohort that are in a risk group (including those identified as severely immunosuppressed) the minimum interval is 56 days

[2] Based on current JCVI guidance, only adults (18+) and those aged 16+ in an at-risk group are eligible for booster doses, however, those that are severely immunosuppressed in this cohort who have received a 3<sup>rd</sup> primary dose will be eligible for a booster dose

[3] AstraZeneca and Spikevax® (Moderna) are not currently authorised for under 18s, however, in exceptional circumstances, where Comirnaty® (PfizerBioNtech) is unavailable or not appropriate for individuals, AstraZeneca and Spikevax® (Moderna) may be considered if approved by a lead clinician

12 to 15 years of age inclusive:

Vaccine Name	Scheduling				Dose Amounts	
	Minimum interval between 1 <sup>st</sup> and 2 <sup>nd</sup> dose [1]	Minimum interval between 2 <sup>nd</sup> and subsequent primary course doses where required [2]	Minimum interval between primary course and booster doses [3]	Minimum interval between booster doses [3]	Primary course	Booster dose
<b>Comirnaty®</b> (PfizerBioNtech)	84 days	56 days	N/A	N/A	0.3ml	0.3ml
<b>AstraZeneca [4]</b>	84 days	56 days	N/A	N/A	0.5ml	0.5ml
<b>Spikevax® [4]</b> (Moderna)	84 days	56 days	N/A	N/A	0.5ml	0.25ml

**Note:**

[1] For individuals in this cohort that are in a risk group (including those identified as severely immunosuppressed) the minimum interval is 56 days

[2] Only those individuals that are severely immunosuppressed in this cohort can be eligible for a 3<sup>rd</sup> primary dose

[3] Based on current JCVI guidance, this cohort is not eligible for boosters

[4] AstraZeneca and Spikevax® (Moderna) are not currently authorised for under 18s, however, in exceptional circumstances, where Comirnaty® (PfizerBioNtech) is unavailable or not appropriate for individuals, AstraZeneca and Spikevax® (Moderna) may be considered if approved by a lead clinician

